Krystal Biotech, Inc. (KRYS) Stock Overview
Explore Krystal Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Krystal Biotech, Inc. (KRYS)
Key Financials
Key Financials
Market Cap
10.2B
P/E Ratio
41.79
EPS (TTM)
$7.98
ROE
0.19%
KRYS Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Krystal Biotech, Inc. (NASDAQ: KRYS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Krystal Biotech, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KRYS on the NASDAQ shows an RSI of 54.31, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $274.31 for the NASDAQ listing.
Key metrics behind Krystal Biotech, Inc.'s NASDAQ-traded stock include a P/E ratio of 41.79 and a market capitalization of 10.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of KRYS on the NASDAQ.